DBCO-PEG4-Val-Cit-PAB-MMAF (CAS 2244602-23-9) is a cutting-edge drug-linker for next-gen ADCs. It combines a DBCO group for copper-free click chemistry, a PEG4 linker for enhanced solubility, and a Val-Cit dipeptide with a PAB carbamate for controlled drug release. The payload, MMAF, is a potent tubulin polymerization inhibitor, ideal for cancer therapies.
In pharmaceutical R&D, this molecule plays a key role in ADC design for targeted cancer treatments. The PEG4-Val-Cit-PAB linker provides stability in the bloodstream and ensures selective release within tumor cells. This precision delivers MMAF directly to cancer cells, reducing off-target effects and boosting treatment efficacy.
Key Features:
- Function: Drug-linker for targeted ADC cancer therapy
- Reactivity: DBCO for rapid click chemistry
- Linker: PEG4 for solubility, Val-Cit for cleavage
- Payload: MMAF for tubulin inhibition
- Applications: ADC development, targeted cancer treatment
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
